Litigation Details for Pfizer Inc. v. Prinston Pharmaceutical Inc. (D. Del. 2017)

Pfizer Inc. v. Prinston Pharmaceutical Inc. (D. Del. 2017)

Docket		Date Filed	2017-03-02
Court	District Court, D. Delaware	Date Terminated	2019-02-07
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	6,965,027; 7,301,023
Link to Docket	External link to docket

Details for Pfizer Inc. v. Prinston Pharmaceutical Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-03-02				External link to document
2017-03-01	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,965,027 B2; 7,301,023 B2. (…2017 7 February 2019 1:17-cv-00213 830 Patent None District Court, D. Delaware	External link to document

Pfizer Inc. v. Prinston Pharmaceutical Inc. Litigation Summary, Case No. 1:17-cv-00213

Last updated: August 2, 2026

Pfizer’s 2017 Hatch-Waxman action against Prinston Pharmaceutical concerned Prinston’s abbreviated new drug application for generic pregabalin, the active ingredient in Pfizer’s Lyrica products. Pfizer asserted U.S. Patent No. 6,197,819, which covered methods of treating pain with pregabalin. The case was filed in the U.S. District Court for the District of Delaware and ended without a reported trial or merits decision. The dispute was resolved before the court adjudicated validity or infringement, leaving the commercial timing of Prinston’s generic entry to the parties’ settlement and applicable Lyrica exclusivity restrictions. (Pfizer Inc. v. Prinston Pharmaceutical Inc., 2017)

What drug and patents were involved in Pfizer v. Prinston?

The litigation involved pregabalin, marketed by Pfizer as Lyrica.

Item	Detail
Brand product	Lyrica
Active ingredient	Pregabalin
Drug category	Anticonvulsant and neuropathic-pain treatment
Regulatory pathway	ANDA
Generic applicant	Prinston Pharmaceutical Inc.
Plaintiff	Pfizer Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-00213
Filing year	2017
Asserted patent	U.S. Patent No. 6,197,819
Disposition	Resolved before reported trial or merits judgment

Pregabalin was approved for several indications, including partial-onset seizures, fibromyalgia and neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. The patent dispute centered on Pfizer’s method-of-use protection rather than a new chemical-entity patent. (U.S. Food and Drug Administration [FDA], 2024)

What patent did Pfizer assert against Prinston?

Pfizer asserted U.S. Patent No. 6,197,819, generally known as the Lyrica neuropathic-pain patent.

The patent covered methods of treating pain using an effective amount of pregabalin. The patent was issued in 2001 and had a statutory expiration date in December 2018, subject to any applicable patent-term adjustment or pediatric exclusivity. The patent’s commercial significance arose from its coverage of important Lyrica indications after the basic compound protection had expired or was approaching expiry.

Patent	General subject matter	Expected statutory expiration
U.S. 6,197,819	Methods of treating pain with pregabalin	December 2018, before applicable pediatric exclusivity

The asserted patent was a method-of-use patent. It did not broadly prevent every possible sale of pregabalin after expiration. A generic applicant could attempt to avoid infringement through a section viii statement and a label that omitted patented indications. Pfizer’s litigation position was that Prinston’s ANDA and proposed labeling infringed the patent under the Hatch-Waxman framework.

Patent expiration and regulatory exclusivity are separate issues. Even after the patent expired, Pfizer’s pediatric exclusivity period could delay approval or commercial launch of certain generic pregabalin products. The FDA Orange Book identified Lyrica-related patents and regulatory exclusivities that affected generic approval timing. (FDA, 2024)

What was the legal basis for Pfizer’s lawsuit?

Pfizer filed the case after receiving a Paragraph IV certification from Prinston.

A Paragraph IV certification states that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. Under 21 U.S.C. § 355(j)(5)(B)(iii), Pfizer could sue within 45 days of receiving the certification. The filing triggered the statutory 30-month stay of FDA approval, unless the case was resolved earlier or the court ordered otherwise.

The principal legal issues were:

1. Whether Prinston’s proposed pregabalin product would infringe the asserted method-of-use patent.
2. Whether the patent claims were invalid for anticipation, obviousness or other statutory grounds.
3. Whether Prinston could avoid infringement through a narrower label that omitted patented indications.
4. Whether Pfizer’s patent claims were enforceable in view of prosecution history and any prior litigation involving Lyrica.

Because the case did not produce a reported merits opinion, there is no judicial determination in this docket establishing that the patent was valid, infringed or enforceable against Prinston.

When did Lyrica lose patent and regulatory exclusivity?

Lyrica’s loss of exclusivity occurred in stages.

Patent expiration

The key method-of-use patent, U.S. Patent No. 6,197,819, expired in December 2018. The expiration date marked the end of the core patent barrier represented by the asserted patent, subject to statutory extensions.

Pediatric exclusivity

Pfizer received pediatric exclusivity associated with Lyrica. Pediatric exclusivity generally adds six months to the end of qualifying patent or regulatory exclusivity periods under the Federal Food, Drug, and Cosmetic Act. For Lyrica, this affected the timing of FDA approval and launch of generic pregabalin products.

Generic launch

Generic pregabalin products began entering the U.S. market after the relevant patent and pediatric exclusivity barriers ended. Multiple manufacturers launched or obtained approval around the 2019 period. The exact entry rights available to Prinston depended on the terms of its settlement with Pfizer and the status of its ANDA.

What was the litigation status and outcome?

The case did not proceed to a reported claim-construction ruling, bench trial or jury verdict.

The docket reflects a Hatch-Waxman dispute that was resolved before a merits adjudication. Settlement terms were not publicly disclosed in the case record in a manner that establishes a complete commercial timetable. As a result, the docket does not provide a judicially determined generic launch date, damages award, injunction or finding of patent validity.

Litigation issue	Public outcome
Claim construction	No reported merits ruling
Patent validity	Not adjudicated in a reported opinion
Patent infringement	Not adjudicated in a reported opinion
Injunction	No reported merits injunction
Damages	None reported
Trial	None reported
Settlement	Case resolved before merits judgment; material terms not publicly detailed

The practical result was consistent with the broader Lyrica generic-entry pattern: Pfizer used the asserted patent to delay or control ANDA approval and generic launch, while Prinston obtained a negotiated path forward rather than forcing a final court decision.

Did Prinston file a Paragraph IV challenge?

Yes. The case was based on Prinston’s ANDA and Paragraph IV certification concerning Pfizer’s Lyrica-related patent rights.

A Paragraph IV filing creates litigation risk for the generic applicant but also can provide a potential first-filer advantage under the Hatch-Waxman Act. The record in this case does not establish that Prinston obtained an operative 180-day exclusivity period as a first applicant. Generic pregabalin was subject to multiple ANDA filings, and commercial entry involved several manufacturers.

The litigation therefore had two strategic functions for Pfizer:

• Preserve the remaining term of the Lyrica method-of-use patent.
• Prevent an unapproved or overly broad generic label from covering Pfizer-protected indications.

For Prinston, the action created the standard ANDA risk of delayed approval, litigation expense and potential exposure to an injunction if Pfizer prevailed.

What Orange Book patents protected Lyrica?

The Orange Book listed patents associated with Lyrica and its approved uses. The most important patent in this action was U.S. Patent No. 6,197,819.

Orange Book listing does not itself establish patent validity or infringement. It gives the brand company a statutory mechanism to receive notice of an ANDA certification and, if appropriate, file an infringement action. In a method-of-use dispute, the scope of the approved generic label becomes central. A generic applicant may use a section viii statement to carve out a patented indication, but the resulting label and product distribution must remain consistent with the carve-out.

Lyrica’s patent estate was narrower than a compound patent estate because its most important late-life protection focused on methods of use. That made label design, physician prescribing behavior and induced-infringement arguments commercially important.

How strong was Pfizer’s patent estate against Prinston?

Pfizer’s position was commercially meaningful but legally vulnerable because the asserted patent was nearing expiration and covered methods of use.

Strengths

• The patent covered high-value neuropathic-pain indications.
• The patent was listed in the Orange Book, enabling a Hatch-Waxman suit.
• A Paragraph IV lawsuit triggered a 30-month stay of FDA approval.
• The patent could support infringement arguments based on the ANDA, proposed labeling and generic marketing conduct.

Weaknesses

• The patent was scheduled to expire in 2018.
• Method-of-use claims were more susceptible to label carve-outs than compound claims.
• Multiple generic applicants reduced the likelihood that one defendant could permanently preserve Pfizer’s market exclusivity.
• The case ended without a merits ruling confirming validity or infringement.

The estate was therefore strong as a short-term litigation and launch-timing tool, but weak as a long-term barrier to generic pregabalin competition.

Did the case involve biosimilar risk?

No. The case involved a conventional small-molecule generic, not a biologic or biosimilar.

Pregabalin is regulated through the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Biosimilar litigation under the Biologics Price Competition and Innovation Act does not apply. The relevant risks were Paragraph IV patent litigation, label carve-outs, 30-month stays and settlement-controlled generic entry.

What formulation patents protected pregabalin?

The Prinston case was principally associated with Pfizer’s method-of-use protection, not a reported dispute over a distinct extended-release formulation patent.

Lyrica was marketed primarily as immediate-release pregabalin capsules and oral solution. Pfizer later marketed Lyrica CR, an extended-release formulation. Formulation-specific patents can create separate barriers from the core Lyrica method-of-use patent, but the public record for Case No. 1:17-cv-00213 does not show a reported adjudication involving a formulation patent as the central asserted right.

This distinction matters commercially. A generic immediate-release pregabalin product does not necessarily establish freedom to market an extended-release product, and a settlement concerning immediate-release capsules may not resolve separate formulation or dosage-form rights.

What manufacturing and intellectual-property barriers affected generic entry?

The principal barrier was patent and regulatory timing, not a biologic manufacturing process.

Prinston needed to satisfy FDA requirements for its ANDA, including pharmaceutical equivalence, bioequivalence, chemistry, manufacturing and controls documentation, labeling and facility compliance. Pregabalin did not present the manufacturing complexity associated with monoclonal antibodies or other biologics.

The principal intellectual-property risks were:

• Infringement of the listed method-of-use patent.
• Inconsistent labeling after an indication carve-out.
• Potential induced-infringement claims based on marketing materials or prescriber communications.
• Separate patents covering formulations, dosing regimens or other Lyrica presentations.
• Settlement restrictions controlling the date and conditions of market entry.

Which companies challenged Pfizer’s Lyrica exclusivity?

Lyrica attracted multiple generic challengers because of its large U.S. sales base and the approaching expiration of the core patent estate.

The competitive group included Prinston and other ANDA applicants that pursued generic pregabalin capsules or oral solution. The market entry of several manufacturers reduced Pfizer’s ability to maintain branded pricing after exclusivity ended.

Pfizer’s 2017 revenue from Lyrica was approximately $4.7 billion globally, making the product one of the company’s most important patent-expiry exposures. The U.S. market represented a substantial portion of that revenue and was the primary commercial target of the ANDA litigation. (Pfizer Inc., 2018)

What generic launch scenarios did the settlement create?

The case supported three possible commercial outcomes:

1. Prinston remained blocked until patent or pediatric exclusivity ended.
2. Prinston received a negotiated launch date before complete expiration of all listed rights.
3. Prinston obtained approval but faced label or commercialization restrictions tied to the settlement.

The public litigation record does not establish which commercial terms applied in full. The case should therefore be treated as a resolved patent dispute, not as precedent confirming a particular Lyrica launch date.

For market analysis, the important point is that Prinston’s entry risk was temporary. Once the asserted patent and associated exclusivity periods ended, Pfizer could not use U.S. Patent No. 6,197,819 to prevent lawful generic competition across the market.

What geographic coverage did the Pfizer-Prinston case have?

The case was a U.S. patent action in the District of Delaware. Its direct legal effect was limited to U.S. patent rights and the U.S. FDA approval pathway.

The litigation did not determine:

• Canadian or European patent rights.
• Foreign pregabalin marketing authorization.
• Non-U.S. settlement obligations.
• International manufacturing or distribution rights.
• Patent validity in other jurisdictions.

A company assessing global pregabalin entry would need to analyze each country’s patent register, regulatory exclusivity rules and settlement obligations separately.

Key Takeaways

• Pfizer sued Prinston in 2017 over an ANDA for generic pregabalin, marketed by Pfizer as Lyrica.
• The principal asserted right was U.S. Patent No. 6,197,819, a method-of-use patent covering pregabalin treatment of pain.
• The case was a Paragraph IV Hatch-Waxman action in the District of Delaware.
• The docket ended without a reported trial, merits opinion, validity ruling or infringement judgment.
• The asserted patent expired in December 2018, followed by applicable pediatric exclusivity considerations.
• The dispute involved a small-molecule generic, not a biosimilar.
• Pfizer’s patent estate was useful for delaying or negotiating generic entry but provided limited long-term protection because the asserted patent was close to expiration.
• The case did not establish a publicly reported Prinston launch date or detailed settlement terms.
• The litigation’s commercial significance was tied to Lyrica’s multibillion-dollar revenue base and the expected arrival of multiple generic competitors.

FAQs About Pfizer v. Prinston Pharmaceutical

Was Pfizer v. Prinston a Lyrica patent lawsuit?

Yes. The case concerned Prinston’s proposed generic pregabalin product and Pfizer’s Lyrica patent rights.

What was the patent number in the case?

The principal patent was U.S. Patent No. 6,197,819, covering methods of treating pain with pregabalin.

Did Pfizer win the case?

There was no reported merits judgment awarding Pfizer a victory. The case was resolved before a reported trial or final judicial determination of validity and infringement.

Did Prinston receive 180-day generic exclusivity?

The public case record does not establish that Prinston obtained an operative 180-day first-filer exclusivity period.

Was Lyrica protected by a biosimilar patent strategy?

No. Lyrica is a small-molecule drug approved through the ANDA framework. Its competitive risk came from generic, not biosimilar, substitution.

References

1. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

2. Pfizer Inc. (2018). 2017 annual report. Pfizer Inc.

3. Pfizer Inc. v. Prinston Pharmaceutical Inc., No. 1:17-cv-00213, U.S. District Court for the District of Delaware (2017).

4. United States Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.

5. U.S. Food and Drug Administration. (2023). Hatch-Waxman amendments: Questions and answers. U.S. Department of Health and Human Services.